The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMyeloma 2022 | Therapeutic approaches for AL amyloidosis
Angela Dispenzieri, MD, Mayo Clinic, Rochester, MN, briefly discusses therapeutic approaches and the importance of clinical trials in the treatment of amyloidosis. Dr Dispenzieri highlights the standard of care for patients with light chain (AL) amyloidosis, and further discusses the ANDROMEDA trial (NCT03201965) evaluating the use of subcutaneous daratumumab plus bortezomib, cyclophosphamide and dexamethasone (Dara-VCd) versus VCd alone for the treatment of AL amyloidosis. To conclude, Dr Dispenzieri highlights the unmet need in therapeutic options for patients with stage IIIb disease. This interview took place at The International Workshop on Myeloma 2022, held in Scottsdale, AZ.
